This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singhal, S. S. Articles by Awasthi, S. Search for Related Content PubMed PubMed Citation Articles by Singhal, S. S. Articles by Awasthi, S.

Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1)

¹ Department of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, Texas and Departments of ² Pathology and ³ Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, Texas

Requests for reprints: Sanjay Awasthi, Department of Chemistry and Biochemistry, 700 Planetarium Place, CPB Room 312, University of Texas at Arlington, Arlington, TX 76019-0065. Phone: 817-272-5444; Fax: 817-272-3808; E-mail: sawasthi{at}uta.edu or sanjay.awasthi{at}usoncology.com.

Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non–small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects. [Cancer Res 2007;67(9):–9] [Cancer Res 2007;67(9):4382–9]

This article has been cited by other articles:

				S. S. Singhal, J. Singhal, S. Yadav, M. Sahu, Y. C. Awasthi, and S. Awasthi RLIP76: A Target for Kidney Cancer Therapy Cancer Res., May 15, 2009; 69(10): 4244 - 4251. [Abstract] [Full Text] [PDF]

				S. Awasthi, S. S. Singhal, Y. C. Awasthi, B. Martin, J.-H. Woo, C. C. Cunningham, and A. E. Frankel RLIP76 and Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4372 - 4377. [Abstract] [Full Text] [PDF]

				S. S. Singhal, S. Yadav, K. Drake, J. Singhal, and S. Awasthi Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1 J. Biol. Chem., July 11, 2008; 283(28): 19714 - 19729. [Abstract] [Full Text] [PDF]